RADARS[®] System Subutex & Suboxone: How Much is Prescribed vs. Abuse/Diversion Reports

> Nabarun Dasgupta, MPH Researcher, RADARS System

Disclosure of Potential Conflicts of Interest


- The RADARS System is a governmental nonprofit operation of the Rocky Mountain Poison and Drug Center, an agency of Denver Health and Hospital Authority, and provides data to industry and researchers on a subscription basis. RMPDC employees only receive their salary for their participation in system operations and research activities.
- Reckitt Benckiser Pharmaceuticals Inc., supported the pediatric analyses through an unrestricted educational grant but did not participate in the study design or analysis.

Outline

- RADARS System Overview
- Buprenorphine Abuse and Diversion Overview
- Buprenorphine Abuse Data: Abstracted
 Poison Center Data
- Buprenorphine Mortality Data
- Buprenorphine Pediatric Exposures

RADARS System Organization


Rocky Mountain Poison & Drug Center of Denver Health



Six Views on Prescription Drug Abuse

Law Enforcement	Drug DiversionCriminal justice perspective
Key Informant	 Dependent/addicted patients Health care provider perspective
Poison Center	 Acute incident – calling for care advice All ages and geographic regions
Opioid Treatment Program	Dependent/addicted patientsPatient perspective
Impaired Health Care Worker	Subset of all signal detection systemsEarly adopter group?
College Survey	ExperimentationEarly abuse perspective

Drug Dependence Pathway




Institute of Medicine – Committee on Opportunities in Drug Abuse Research. *Pathways of Addiction*. Washington, DC: National Academy Press; 1996.

Buprenorphine Abuse and Diversion Overview

RADARS[®] System


RADARS System Signal Detection **Studies** Abuse & Diversion Rates


2002-07



Abuse, Misuse and Diversion Rates per 1,000 URDD


Drug Diversion






Quarter/Year

Opioid Treatment Program



Poison Center




Key Informant

Buprenorphine Rates per 1,000 URDD


3rd Quarter 2007

Drug Diversion

Key Informant



Unique Recipients of Dispensed Drug (URDD)




Buprenorphine Endorsement

Table 1 Opioid abuse among MMTP enrollees, by primary drug of choice

	Prescription opioid $(n = 2174)$ (%)	
	Ever	Past 30 days
Heroin	33	13
Prescription opioids	100	99
Oxycodone, any formulation	89	79
CR-Oxycodone (e.g., OxyContin®)	89	71
IR-Oxycodone (e.g., Percocet [®])	81	59
Hydrocodone (e.g., Vicodin®)	88	67
Methadone	58	40
Morphine	59	29
Hydromorphone (e.g., Dilaudid [®])	37	16
Fentanyl	30	9
Buprenorphine	5	1
Ever injected primary drug	33	n/a

Rosenblum, et al. Drug Alcohol Dependence 2007;90:64-71.

RADARS System College Survey Abuse & Misuse by Self Identified College Students



Opioid

Buprenorphine Abuse Data: Abstracted Poison Center Data

RADARS[®] System


Buprenorphine Case Abstraction Methodology

- Data collected from 2003 2007Q2
 - 11 of 60 US centers (18%) in 1st quarter 2003
 - 43 of 60 US centers (72%) in 2nd quarter 2007
- All intentional exposure case notes were reviewed for abuse
 - "injected", "snorted", "abused", "to get high", "recreationally", and similar terms

Buprenorphine Case Abstraction Results

- 125 cases were abuse cases as defined in the methodology
- Mean age: 27 years
- 65% male
- 7% of the case notes described chronic buprenorphine abuse

Route of Exposure



Buprenorphine Poison Center Mortality Data RADARS® System

Mortality Data Methodology

- Poison center "associated medical outcome"
- Poison center intentional exposures
- Data collected from 2003 2007Q3
 - 11 of 60 US centers (18%) in 1st quarter 2003
 - 43 of 60 US centers (72%) in 3rd quarter 2007
- 5 deaths associated with buprenorphine intentional exposures
- Not causally linked to death

Buprenorphine Pediatric Exposures

RADARS[®] System

Rx Opioid Pediatric Exposures								
RADARS System Poison Center 2003 - 2006								
	Buprenorphine	Hydrocodone	Fentanyl	Oxycodone				
	(n=176)	(<i>n</i> =6,003)	(n=123)	(n=2,036)				
Age Mean (SD)	2.1 (0.9)	2.3 (1.2)	2.0 (1.2)	2.1 (1.1)				
Male N (%)	99 (56.3)	3,232 (53.9)	64 (52.5)	1,081 (53.5)				
	Referent	OR 1.1 (0.81, 1.5)	OR 1.2 (0.75, 1.89)	OR 1.1 (0.83, 1.54)				
Site N (%)								
Own Home	169 (96.0)	5,581 (93.0)	111 (90.2)	1,821 (89.4)				
	Referent	OR 1.8 (0.85, 3.91)	OR 2.6 (1.00, 6.83)	OR 2.8 (1.32, 6.15)				
Other Home	3 (1.7)	335 (5.6)	4 (3.3)	155 (7.6)				
Route N (%)								
Ingestion	175 (99.4)	5,993 (99.8)	77 (62.6)	2,020 (99.1)				
	Referent	OR 0.29 (0.04, 2.30)	OR 104.5 (14.2, 771)	OR 1.39 (0.18,10.5)				

Rx Opioid Pediatric Exposures RADARS System Poison Center 2003 - 2006

	Exposure Mentions (URDD Rate)	Mentions Associated with Major Outcome (URDD Rate)	Mentions Associated with Death (URDD Rate)
Buprenorphine	0.5	0.02	0
Fentanyl	0.03	0.0008	0
Hydrocodone	0.06	0.00006	0.00002
Hydromorphone	0.06		
Methadone	0.2	0.006	0.0008
Morphine	0.1	0.001	0
Oxycodone	0.06	0.0003	0.0001

Conclusion

- Buprenorphine abuse and diversion appears to be localized, but occurs in many parts of the country
- While there was an initial increase in abuse/diversion reports, rates appear to have stabilized or decreased since 2006
- Buprenorphine abuse/diversion follow similar patterns to other opioids

Acknowledgements

Key Informant Signal Detection System

Theodore J. Cicero, PhD, *Principal Investigator*, Washington University at Saint Louis Alethea Paradis, *Project Manager*, Washington University at Saint Louis Yuhong Tian, PhD, Washington University at Saint Louis

Drug Diversion Signal Detection System

James A. Inciardi, PhD, *Principal Investigator*, University of Delaware Hilary Surratt, PhD, *Co-Principal Investigator*, University of Delaware Yamilka Lugo, *Research Associate II*, University of Delaware

Opioid Treatment Program Signal Detection System

- Mark Parrino, MPA, *Principal Investigator*, American Association for the Treatment of Opioid Dependence (AATOD)
- Andrew Rosenblum, PhD, *Co-Principal Investigator*, National Development and Research Institutes, Inc. (NDRI)
- Carleen Maxwell, *Project Director*, American Association for the Treatment of Opioid Dependence (AATOD)
- Chunki Fong, *Project Director and Senior Methodologist*, National Development and Research Institutes, Inc. (NDRI)

RADARS System Contact

Elise Bailey, MSPH RADARS System Manager Rocky Mountain Poison and Drug Center (303) 739-1297 Elise.Bailey@rmpdc.org